Print Page   Close Window

Press Release

POZEN Receives Expanded Patent Coverage For MT 400 Technology

CHAPEL HILL, N.C.--(BUSINESS WIRE)--July 8, 2003--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company developing therapeutic advancements in a cost effective manner, today announced that the United States Patent and Trademark Office has issued patent number 6,586,458 with claims providing protection for its MT 400(TM) technology. MT 400 technology is POZEN's proprietary combination of long-acting non-steroidal anti-inflammatory drugs and triptans that may improve the effectiveness of acute treatment and provide sustained pain relief for patients suffering from migraine headaches.

The new patent strengthens the company's patent protection for MT 400 technology by providing additional claims relating to pharmaceutical compositions and treatment methods that can be used for migraine patients. POZEN now owns three patents in the U.S. and one patent in Australia for its MT 400 technology. Additional patent applications for MT 400 technology are pending in the U.S., Canada, Europe, and Japan.

POZEN announced on June 12, 2003 that it signed a licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of a novel migraine treatment using MT 400 technology. Rights under this newly issued patent are included in the licensing agreement with GSK.

POZEN is a pharmaceutical company developing therapeutic advancements in a cost effective manner. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. Product development efforts are focused on diseases with unmet medical needs where POZEN can improve efficacy, safety, and/or patient convenience. The company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN." For detailed company information, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and FDA approval of our product candidates, resulting in, among other things, our failure to achieve milestones that would have provided us with revenue; our inability to enter into or maintain, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales, and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2003 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Matt Czajkowski
Chief Financial Officer
Lisa Barthelemy
Director, Investor Relations